Aptamer Patents: Who Leads, Where the Gaps Are 2026
- 23.9% of all 3,158 records sit with just five assignees, but the tenth-ranked filer already holds only 41 records — the concentration breaks down fast outside the leaders.
- Filings peaked in 2021 at 237 and have declined since, with 2017's 148 now roughly matching the tail end of the trend rather than its start.
- C40B combinatorial-library claims sit at just 4.1% of records versus 82.1% for core C12N genetic-engineering claims — the selection-methodology layer is comparatively open.
What the patent record shows about aptamer IP
Aptamer patents cluster around three technical layers: the nucleic-acid chemistry itself (C12N, genetic engineering; C07H, sugars and nucleic acids), the therapeutic application of that chemistry (A61K medicinal preparations and A61P therapeutic activity), and the diagnostic and assay use (G01N and C12Q). This dataset spans 3,158 records filed between 2015 and mid-2026 and captures claims built around nuclease resistance, binding affinity, counter-selection and renal clearance — the properties that determine whether an aptamer candidate survives past bench chemistry into a usable diagnostic or drug.
Filing activity rose through the late 2010s, peaked in 2021, and has since declined — a pattern consistent with a technology that went through a concentrated period of platform-building rather than one still in early expansion. Publication lags filing by roughly 18 months, so the most recent year's count understates real filing activity; treat 2025 and 2026 figures as provisional.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 3,158-record dataset: how filing volume has moved year over year, and how records distribute across IPC subclasses. Because a single record can carry several IPC codes, the subclass shares sum to more than 100%.
A decade of filing activity, now past its peak
Filings climbed from 148 in 2017 to a peak of 237 in 2021, sat at 184 by the 2022 midpoint, and have fallen since — 2026's count of 11 is a partial year, but the trajectory from 2022 onward is downward rather than flat.
Genetic engineering claims dominate; library methods are thin
C12N covers 82.1% of the 3,158 records, with A61K medicinal preparations (41.5%) and G01N testing (35.8%) close behind. C40B, the combinatorial-library classification tied to SELEX-style selection methods, covers only 4.1% of records — a sign that selection methodology itself is comparatively under-claimed next to the molecules it produces.
Shares are the percentage of the 3,158 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Aptamer-Based Therapeutics and Diagnostics with Eureka
This page is one run against one query. Ask Eureka your own question about aptamer-based therapeutics and diagnostics and every answer comes back with the patent numbers behind it.
Try EurekaThe patents everyone in this space cites
EP1143980A4 — Thio-modified aptamer compositions and production methods
Filed by the Board of Regents of the University of Texas System, this application covers compositions and production methods for thio-modified aptamers — a chemical modification route aimed at improving nuclease resistance, a recurring constraint across the dataset's therapeutic-use claims.Number, assignee and filing date are rendered from the underlying record.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5681702A | Reduction of nonspecific hybridization by using novel base-pairing schemes | 623 |
| 2 | WO1992014843A1 | Aptamer specific for biomolecules and method of making | 609 |
| 3 | US20040249130A1 | Aptamer-toxin molecules and methods for using same | 385 |
| 4 | US20040022727A1 | Aptamer-toxin molecules and methods for using same | 326 |
| 5 | US5780610A | Reduction of nonspecific hybridization by using novel base-pairing schemes | 283 |
| 6 | US20150301058A1 | Biomarker compositions and methods | 249 |
| 7 | US6699843B2 | Method for treatment of tumors using nucleic acid ligands to PDGF | 212 |
| 8 | WO2014191359A1 | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | 191 |
| 9 | US20160231324A1 | Encapsulated sensors and sensing systems for bioassays and diagnostics and methods for making and using them | 188 |
| 10 | US20070117112A1 | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts | 183 |
Citation counts inside a searched corpus favour older filings — treat these as markers of foundational influence, not current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for R&D and IP strategy
Three patterns stand out once the filing trend, the citation table and the IPC composition are read together.
Leadership is real but shallow
The leading assignee holds 275 records and the top five combine for 23.9% of all 3,158 records in scope. But the fifth-ranked filer already sits at 68 and the tenth at 41 — the drop-off from leader to mid-table is steep, meaning the field is not a two-player race so much as one strong leader ahead of a wide, active field.
Filing activity has cooled since 2021
The trend rose from 148 filings in 2017 to a peak of 237 in 2021, then declined toward the 2022 midpoint of 184 and further beyond. Several of the most active historical filers show zero filings in the latest tracked year — consistent with a maturing claim base rather than continued platform expansion.
Selection methods are thinly claimed next to the molecules
C12N genetic-engineering claims cover 82.1% of records, but C40B combinatorial-library claims — the classification most closely tied to SELEX-style selection processes — cover only 4.1%. That gap suggests the underlying selection methodology is less densely fenced than the resulting aptamer compositions themselves.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to aptamer-based therapeutics and diagnostics, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Archemix Corp. | WILSON CHARLES | 18 |
| RIBOMIC Inc. | Otsuka Pharmaceutical Co., Ltd. | 16 |
| Archemix Corp. | EPSTEIN DAVID | 14 |
| POSTECH Academy-Industry Foundation | POSCO | 14 |
| RIBOMIC Inc. | Shionogi & Co., Ltd. | 13 |
| Rheinische Friedrich-Wilhelms-Universität Bonn | STIFTUNG CAESAR | 11 |
| SomaLogic Operating Co., Inc. | Quest Diagnostics Investments Inc. | 10 |
| Archemix Corp. | KURZ MARKUS | 10 |
Only 10 co-assignee pairs appear in the dataset, and even the strongest pairing tops out at 18 shared records — most activity here is filed by single assignees rather than joint ventures or research partnerships.
Who holds the ground, and where the gate sits
The assignee ranking covers 100 companies counted across the 3,158 records in scope — not a top-50 or top-100 cut, but the full ranking the dataset returns.
One filer well ahead of the field
The top-ranked assignee holds 275 records, more than four times the fifth-place filer's 68 — a gap wide enough to suggest an early-mover platform position built over multiple filing cycles rather than a recent surge.
A broad, active mid-tier
By the tenth position the count has fallen to 41 records, and the field includes universities and research institutes alongside corporate filers — indicating aptamer IP is being built as much in academic technology-transfer offices as in industry labs.
Momentum has gone quiet at the top
Multiple assignees that built large historical portfolios show zero filings in the most recent tracked year, with some marked at -100% year-on-year. Given the roughly 18-month publication lag, this understates true current activity, but the direction across the ranked leaders is toward slower filing rather than faster.
| Assignee | Recent year | YoY |
|---|---|---|
| SomaLogic Operating Co., Inc. | 0 | -100% |
| Archemix Corp. | 0 | — |
| RIBOMIC Inc. | 0 | — |
| Procter & Gamble Co. | 0 | -100% |
| MeiraGTx UK II Ltd. | 0 | — |
| Board of Regents, The University of Texas System | 0 | -100% |
| University of Cincinnati | 0 | -100% |
| Rheinische Friedrich-Wilhelms-Universität Bonn | 0 | -100% |
Where to take this analysis
The dataset points to specific follow-up questions depending on whether the goal is freedom-to-operate, licensing, or R&D prioritisation.
Check freedom-to-operate against the citation leaders
The most-cited records in this dataset date back to core base-pairing and aptamer-toxin filings; any new therapeutic or diagnostic candidate should be checked against these before design work goes further.
Run a claims check in EurekaMap the under-claimed selection-method layer
With C40B combinatorial-library claims covering only 4.1% of records against 82.1% for core genetic-engineering claims, selection methodology is a narrower target for a defensible first claim.
Explore white space in EurekaTrack the leader's recent filing pattern
The top assignee's zero-filing latest year, read against the 18-month publication lag, is worth monitoring rather than treating as a settled retreat from the space.
Set up assignee tracking in EurekaCommon questions about aptamer patents
One assignee leads the ranked field with 275 records, well ahead of the fifth-placed filer at 68 and the tenth at 41. The gap between first and fifth place shows a genuine leadership position rather than a tightly bunched top tier. Outside the top ten, the ranking spreads across 100 companies including several university and hospital-system filers, so the field is broader than a single dominant player would suggest.
Filings rose from 148 in 2017 to a peak of 237 in 2021, then declined toward 184 by 2022 and further afterward. The trend since the 2021 peak points to a maturing rather than expanding claim landscape. Because publication lags filing by roughly 18 months, the most recent one to two years in any such dataset will always look lower than actual filing activity turns out to be.
The dataset's IPC composition shows C12N (microorganisms and genetic engineering) covering 82.1% of the 3,158 records, with A61K (medicinal preparations) at 41.5%, G01N (material analysis and testing) at 35.8%, and C12Q (enzyme/DNA-based measuring and testing) at 34.5%. Smaller categories include A61P therapeutic activity (21.6%), C07H sugars and nucleic acids (17.8%), C07K peptides and proteins (8.6%), and C40B combinatorial libraries (4.1%). Because records often carry multiple IPC codes, these shares add up to more than 100%.
The clearest signal is the gap between C12N genetic-engineering claims at 82.1% of records and C40B combinatorial-library claims at just 4.1% — the SELEX-style selection methodology that produces aptamers is comparatively lightly claimed compared with the resulting molecules. Counter-selection protocols, renal clearance modification chemistry and point-of-care assay formats also show thinner filing density relative to the core chemistry classes. These are not guarantees of clear freedom-to-operate, but they mark areas where fewer claims currently compete for the same ground.
EP1143980A4, filed by the Board of Regents of the University of Texas System, covers compositions and production methods for thio-modified aptamers, a chemistry route aimed at improving nuclease resistance. Whether it blocks a specific new filing depends on how closely that work's claims track the same modification chemistry and production method, which requires a direct claims comparison rather than a title-level read. Given its 2003 priority date and the field's subsequent filing activity, it sits among the older, foundational documents that later applicants have had to design around or license.
Research Aptamer-Based Therapeutics and Diagnostics in depth with Eureka
Go past this page: query the whole aptamer-based therapeutics and diagnostics corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.